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Little Rock, Arkansas
Angiotensin-converting enzyme inhibitors are effective
vasodilators in the treatment of congestive heart failure.
Enalapril, a new angiotensin-converting enzyme inhib-
itor, or placebo, in addition to digoxin and diuretic drugs,
were given to 17 patients with chronic congestive heart
failure who were followed up for 12 weeks. In random
double-blind fashion, nine patients received enalapril
and eight received placebo. Cardiac dimensions and
function improved slightly but insignificantly in both
groups. Treadmill exercise duration increased from a
mean value (± standard deviation) of 9.1 ± 3.2 to 12.0
± 3.5 minutes during enalapril administration (p <
0.025) and was unchanged during placebo administra-
The renin-angiotensin system is important in the pathogen-
esis of congestive heart failure. and inhibitors of angioten-
sin-converting enzyme are beneficial in patients with chronic
left ventricular failure (1-5). Captopril is the only currently
available oral angiotensin-converting enzyme inhibitor. and
it may produce rash and dysgeusia as well as rare. but
serious, renal dysfunction and neutropenia (6). The toxicity
of captopril may be related to its sulfhydryl content (7.8).
Enalapril is a new. orally active angiotensin-converting en-
zyme inhibitor that does not contain a sulfhydryl group and
is more potent and longer-acting than captopril (9-11).
In clinical trials. enalapril has effectively lowered blood
pressure in hypertensive patients and improved hemody-
namics in patients with heart failure (12-16). Current ex-
perience with enalapril in heart failure has been limited to
uncontrolled trials showing improved hemodynamics.
symptoms and exercise capacity (14-16). Initial uncon-
trolled experience with other vasodilators. such as prazosin
and hydralazine, led to much enthusiasm. but subsequent
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tion 00.1 ± 3.7 versus 11.1 ± 5.2 minutes). Maximal
oxygen consumption also increased during enalapril
therapy (15.8 ± 3.4 to 18.4 ± 4.4 ml/min per kg, p <
0.05) and remained unchanged during placebo treatment
06.0 ± 6.4 versus 17.0 ± 4.6 ml/min per kg). Clinical
functional class (Yale scale) improved 3.1 ± 1.9 points
(p < 0.01) during enalapril treatment but not during
placebo treatment (0.8 ± 3.5 points, no significant dif-
ference). No significant side effects were observed.
Thus, enalapril appears to be a clinically effective
and useful new angiotensin-converting enzyme inhibitor
for the management of chronic congestive heart failure.
(J Am Coli CardioI1985;5:101-7)
controlled trials showed neither of these agents to be dif-
ferent from placebo (17-21). Therefore. the present study
was designed to assess the effects of long-term administra-
tion of enalapril compared with placebo in a double-blind
randomized trial in patients with chronic left ventricular
failure.
Methods
Patient selection. Patients of both sexes. aged 21 to 70
years and with a history of chronic congestive heart failure
of at least 3 months' duration while taking digitalis and
diuretic drugs, were selected for study. Congestive heart
failure was diagnosed by a history of exertional symptoms
(functional class II to IV by criteria of the New York Heart
Association) and the presence of a ventricular gallop sound,
jugular venous distension. pulmonary rales or otherwise
unexplained peripheral edema. In addition, a left ventricular
ejection fraction less than 41% must have been documented
by radionuclide or contrast angiography within the previous
month.
The cause of congestive heart failure was coronary artery
disease. diagnosed by a history of documented acute myo-
cardial infarction or coronary arteriography, or idiopathic
dilated cardiomyopathy, diagnosed when no other cause of
heart failure was apparent. Patients were excluded from the
study if any of the following were present: primary valvular
heart disease. obstructive cardiomyopathy, acute myo-
0735·1097/85/$3.30
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cardial infarction within 3 months, hypertension requiring
more than diuretic treatment, primary lung disease, angina
pectoris or inability to exercise for any reason other than
dyspnea or fatigue. Patients meeting the selection criteria
gave written informed consent and entered the baseline pe-
riod. The study protocol was approved by the local Human
Investigation Committees in June 1982.
Stabilization. At entry into the baseline period, pa-
tients were weighed and thoroughly examined, any vaso-
dilator drugs were stopped and digitalis and diuretic doses
were adjusted as needed. One week later, if clinical status,
weight and medications were stable, an exercise test was
performed using a modified Naughton treadmill protocol.
Exercise was performed to symptomatic maximum of dysp-
nea or fatigue and was not terminated for any other reason.
Expired air was collected during exercise for on-line mea-
surement of oxygen consumption, carbon dioxide produc-
tion and ventilatory exchange ratio. The ventilatory ex-
change ratio was used to indicate the achievement of anaerobic
threshold, and an increase during exercise of at least 0.15
or to an absolute value above I was required for an exercise
test to be considered valid. In addition, total duration of
exercise had to be between 4 and 16 minutes. The exercise
protocol has been extensively used and previously described
by us (4,5,16,21-24). Patients were continued for I more
week in the baseline period, and at the end of the second
baseline week, if symptoms were stable, medications un-
Table 1. Qualifying Patient Characteristics
changed and weight varied less than 3% from the previous
week, exercise testing was repeated. If exercise duration
remained between 4 and 16 minutes and varied less than 2
minutes from the first exercise test, patients were considered
in stable condition and eligible for randomization,
Randomization and follow-up. Before randomization,
baseline blood samples for routine blood chemistry values
and plasma renin activity were obtained. An electrocardio-
gram, chest X-ray film, echocardiogram and left ventricular
ejection fraction by radionuclide angiography were ob-
tained, Patients were then hospitalized for test dosing with
open-label enalapril, 5 mg twice daily on the first day. The
dose was increased to 10 mg twice daily on day 2 if systolic
blood pressure decreased less than 10 mm Hg during the
first day or no symptomatic hypotension occurred, At the
completion of the dose titration period, on the second or
third day of hospitalization, patients received the first dose
of the test drug, enalapril or placebo, given in random dou-
ble-blind fashion, Patients were discharged from the hospital
the following day receiving enalapril or placebo twice daily,
The patients were seen in clinic every 2 weeks for 12
weeks, during which digitalis dosage was held constant and
diuretic dosage was adjusted as needed. The test medication
dosage could be titrated upward by 5 to 10 mg twice daily
after the first :2 weeks if symptoms or exercise tolerance
were not improved. Test drug doses were maintained con-
stant thereafter. At each visit, patients were weighed and
Case Age
(no.) (yr)
Enalapril
1 50
2 61
3 53
4 57
5 61
6 52
7 47
8 64
9 67
Mean 56.9
± SD 6.9
Placebo
10 62
II 69
12 56
13 67
14 55
15 64
16 35
17 42
Mean 56.3
± SD 12.1
Diagnosis
IDC
CAD
CAD
IDC
CAD
IDC
IDC
IDC
IDC
IDC
CAD
IDC
IDC
IDC
IDC
IDC
IDC
Functional Duration of LVEF
Class* CHF (rno) (%)
3 84 16
3 23 19
3 21 18
3 4 19
3 28 23
3 30 9
3 240 34
4 16 24
3 9 17
3.1 50.6 19.9
0.3 74.7 6.8
3 4 21
3 22 39
3 10 20
4 120 34
4 26 24
3 24 20
3 40 23
3 36 23
3.3 35.3 25.5
0.5 36.3 7.1
* By criteria of the New York Heart Association. No differences between groups are statistically significant.
CAD == coronary artery disease; CHF == congestive heart failure; IDC = idiopathic dilated cardiomyopathy;
LVEF == left ventricular ejection fraction; SD = standard deviation.
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Table 2. Effects of Long-Term Enalapril Administration in Patients With Congestive Heart Failure
Enalapril (n .' 81 Placebo (n = 8)
Control Treated Control Treated
SBP (rnm Hg) 1134 ± 17.7 107.3 ± 1.1.7 121.1 ± 6.5 133.5 ± 25.0*
OBP (mrn Hg) 7.'>.3 ± 13.5 73.6 ± 94 78.3 ± 7.0 ~U.O ± 12.2
HR (beats/min) 85.7 ± 143 88.9 ± 17.8 818 ± 13.2 73.3 ± 12.0*
Body weight (kg) 81.8 ± 8.8 82.2 ± 10.2 81.1 ± 17.9 80.7 ± 17.2
CTR (%) 56.3 ± 5.0 53.6 ± 6.6 54.5 ± 44 54.2 ± 4.2
LVOO (rnm) 64.5 ± 6.8 65.3 ± 8.4 67.3 ± 134 69.9 ± 8.6
LVEF(%j 18.0 ± 44 23.3 ± 1.'.5 27.8 ± 114 31.3 ± 16.3
*p < 0.05 compared with control. Values shown represent mean ± standard deviation. Control values are those before randomization at the end of
the stabilization period; treated values are those 12 weeks after randomization. No differences between groups at control are statistically significant. CTR
= cardiothoracic ratio; OBP = diastolic blood pressure; HR = heart rate; LVDD = left ventricular diastolic dimension; LVEF = left ventricular
ejection fraction; SBP = systolic blood pressure.
examined. and symptomatic status was assessed using the
Yale scale, which scores severity of symptoms from 0 to
12 being most severe (25). Other measurements. including
exercise testing. were repeated at weeks 2. 6 and 12.
Statistical analysis. Unpaired t tests were used to com-
pare responses betweenenalapril- and placebo-treated groups.
Changes within groups were compared by paired t tests if
indicated after performing an analysis of variance for serial
observations.
placebo. There were no statistically significant differences
between treatment groups in qualifying characteristics at
entry into the study (Table I). All patients were receiving
digoxin and diuretic drugs, Antiarrhythmic drugs were being
taken by four enalapril- and three placebo-treated patients
at entry. Three patients in each group had been taking vas-
odilators. Only one patient in the enalapril group had the
study drug dose increased to 10 mg twice daily after the
Results
Patient characteristics. Of 17 patientsentering the study,
9 were randomized to receive enalapril and 8 to receive
Figure 1. Effects of long-term enalapril administration (9 patients,
left) and placebo (8 patients, right) on maximal oxygen con-
sumption during exercise in 17 patients with congestive heart fail-
ure. Probability (p) values represent comparisons with enalapril
control. Mean values ± standard deviation are plotted.
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initial dose titration; all others remained on the lowest dose
of 5 mg twice daily. Three patients in the placebo group
had their study drug dose increased to 10 mg twice daily.
Only one patient in the enalapril group (Case 7) voluntarily
withdrew from the study 6 weeks after randomization be-
cause she was unable to secure transportation to and from
the clinic. All other patients completed the 12 week follow-
up period.
Plasma renin activity. Because angiotensin-converting
enzyme inhibition results in increased plasma renin activity,
levels of plasma renin activity were analyzed as an index
of sustained drug action. Pretreatment levels of plasma renin
activity were similar in the two groups and increased from
a mean value (± standard deviation) of 9.0 ± 6.7 to 21.5
± 23.9 ng/ml per hour by the end of the treatment period
in the enalapril-treated group (p < 0.05), while remaining
unchanged at 9.2 ± 12.7 ng/ml per hour in the placebo-
treated group. The normal range for plasma renin activity
in our laboratory is 0.2 to 4 ng/ml per hour. This result
indicates sustained effective angiotensin-converting enzyme
inhibition during enalapril administration.
Bodyweight, cardiac dimensions, hemodynamics and
ejection fraction. Effects of treatment on body weight,
cardiac dimensions and hemodynamics are summarized in
Table 2. There were no statistically significant differences
between groups for control values. Body weight did not
change significantly during treatment in either group. Blood
pressure and heart rate did not change significantly during
enalapril administration, whereas blood pressure increased
significantly and heart rate decreased significantly during
placebo administration. Cardiothoracic ratio and left ven-
tricular diastolic dimension were similarly increased at con-
trol in both groups and did not change significantly during
treatment in either group. Left ventricular ejection fraction
at randomization was depressed in both groups and increased
slightly but insignificantly in both groups by the end of the
treatment period.
Exercise capacity. Exercise capacity increased signifi-
cantly during enalapril but not placebo administration (Fig.
I). Maximal oxygen consumption, which averaged 15.8 ±
3.4 mllmin per kg at control in the enalapril group, increased
significantly to 19.5 ± 3.8 mllmin per kg by 6 weeks (p
< 0.05) and remained increased at 18.4 ± 4.4 mllmin per
kg after 12 weeks (p < 0.05). Exercise duration also in-
creased significantly from 9.1 ± 3.3 minutes at control to
12.0 ± 3.5 minutes after 12 weeks of enalapril treatment
(Fig. 2). In the placebo group, control maximal oxygen
consumption of 16.0 ± 6.4 mllmin per kg (Fig. I) and
exercise duration of 10.1 ± 3.7 minutes (Fig. 2) were not
significantly different from the enalapril group. The slight
increases in maximal oxygen consumption and exercise du-
ration during placebo administration never achieved statis-
tical significance. The increase in exercise duration after 12
Figure 2. Effects of long-term enalapril administration and pla-
cebo on exercise duration in the same 17 patients with congestive
heart failure, Probability (p) values represent comparisons with
enalapril control. Mean values ± standard deviation are plotted.
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weeks averaged 45.3 ± 59.5% in the enalapril-treated group
(p < 0.05) and only 7.4 ± 13.8% in the placebo-treated
group (p == NS).
Clinical course. Changes in clinical symptomatic status
paralleled changes in exercise capacity. The Yale scale score
at control was similar in both groups, averaging 7.9 ± 1.6
in enalapril-treated patients and 7.8 2:: 2.8 in the placebo-
treated group. The Yale scale score decreased significantly
throughout treatment in the enalapril group and was not
significantly changed during placebo administration (Fig.
3). The Yale scale score was reduced by an average of 3.]
± I. 9 points after 12 weeks of enalapril (p < 0.01) com-
pared with a reduction of only 0.8 2:: 3.5 points after 12
weeks of placebo administration (p == NS).
No major clinical events or side effects occurred in either
treatment group. Laboratory tests, including white blood
cell count, serum creatinine, serum potassium and urinary
protein content, did not change significantly in either group
and no marked individual changes occurred. Orthostatic
dizziness occurred transiently in four enalapril- and two
placebo-treated patients. This resolved with no treatment or
with a reduction in diuretic dosage. One patient taking en-
alapril developed atrial fibrillation with rapid ventricular
response and increased dyspnea: this was controlled promptly
with an increase in digoxin dosage. One placebo-treated
patient had worsening exertional dyspnea and one patient
receiving placebo developed transient mild chest pain. Di-
uretic drugs were increased in three enalapril-treated patients
because of fluid retention, and diuretic drugs were decreased
in two enalapril-treated patients who developed orthostatic
hypotension. Diuretic dosage was unchanged in the placebo
group. No patient developed a skin rash or alteration of
taste, but one enalapril-treated patient noted the onset of
new generalized mild pruritis and impotence.
Discussion
Efficacy of enalapril. The angiotensin-converting en-
zyme inhibitor, captopril, is the only vasodilator currently
approved for use in chronic congestive heart failure, pri-
marily as a result of its demonstrated efficacy in improving
symptoms and exercise tolerance in a placebo-controlled
trial (5). Several vasodilators have improved hemody-
namics, left ventricular performance, symptoms and exer-
cise capacity in uncontrolled trials in patients with heart
failure (17-19,26). However, when subjected to controlled
trials, these same agents have not been different from pla-
cebo in altering symptoms or exercise capacity despite pro-
ducing sustained significant improvements in hemody-
namics and left ventricular performance (20,21,27). Thus,
controlled studies seem mandatory to establish the safety
and efficacy of therapeutic interventions in heart failure.
Our study evaluated the efficacy of long-term enalapril
administration compared with placebo in similar patients
Figure 3. Effects of long-term enalapril administration and pla-
ceboon symptomatic status in the same 17patientswithcongestive
heart f~ilure. Probability (p) values represent comparisons with
enalapril control. Mean values ± standard deviation are plotted.
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with chronic left ventricular failure. The angiotensin-inhib-
iting effect of enalapril was maintained over a 3 month
period as evidenced by a significant increase in plasma renin
activity. This sustained activity of enalapril is consistent
with earlier reports (14) of sustained reduction of systemic
vascular resistance in patients with heart failure treated with
enalapril. We also observed significantly increased exercise
capacity in our enalapril-treated patients, but not in those
receiving placebo. These findings thus confirm previous
uncontrolled trials ( 14-16) of enalapril in heart failure. The
magnitude of increase in exercise duration in our enalapril-
treated patients averaged 35 to 40% more than in the pla-
cebo-treated patients and is similar to that reported for the
Multicenter Captopril Trial (5). Although hemodynamic re-
sponses to enalapril in patients with heart failure have been
less pronounced than those produced by captopril (14-16),
clinical efficacy of these two angiotensin-converting enzyme
inhibitors appears similar. This is consistent with recent
observations (28,29) that long-term clinical effects of cap-
topril and other vasodilators are not related to initial hemo-
dynamic responses. It should be noted that the present study
design using parallel groups instead of a crossover design
was patterned after the Multicenter Captopril Trial and yielded
similar results (5).
Side effects. We did not observe any serious side effects
caused by enalapril, which has generally not been associated
with significant toxicity or side effects in patients with heart
failure or hypertension (12-16). Prior experience with cap-
topril may have influenced selection of patients to receive
enalapril in clinical trials. During long-term administration
of enalapril to patients with heart failure DiCarlo et al. (15),
employing doses of 20 mg daily, noted significant hypo-
tension and fluid retention. Neither we nor Cody et al. (14),
using 10 mg per day, observed significant hypotension or
a general need for additional diuretic drugs. However, among
the nine enalapril-treated patients, diuretic drugs had to be
increased in three and decreased in two. Fluid retention has
not been a problem with long-term captopril treatment of
heart failure (3-5).
Therapeutic implications. Enalapril is an effective, long-
acting angiotensin-converting enzyme inhibitor that produces
sustained vasodilation in association with significant im-
provement in symptoms and exercise capacity in comparison
with placebo in patients with chronic left ventricular failure.
Major side effects were not observed. The possibly greater
safety combined with longer duration of action of enalapril
suggests that this compound may ultimately be preferred to
captopril. Since clinical efficacy of these two angiotensin-
converting enzyme inhibitors appears comparable, enalapril
offers an alternative for patients who develop side effects
to captopril since preliminary data indicate no cross-reac-
tivity (30). Of course. this study has addressed effects of
treatment only on symptomatic status and functional ca-
pacity. Larger trials are needed to answer important ques-
tions concerning safety and effects on morbidity and mor-
tality from heart failure.
We are indebted to Marilyn Levinson, LPN and Penny Casebolt. RN for
their skillful and valuable technical assistance.
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